Clinical Trial Update: Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS [Phase 2]

View source ↗

Summary

Phase 2 trial update of multi-modality treatment with Ruxolitinib, Decitabine, and donor lymphocyte infusion after stem cell transplant in AML/MDS shows complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myeloid and Monocytic Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Donor Lymphocyte Infusion
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2023-11-07